2024-05-03 12:47:06 ET
Summary
- Vir Biotechnology, Inc. reported its first-quarter earnings after the bell on Thursday, giving its shareholders some positive tidbits.
- The company continues to have a cash balance higher than the stock's market capitalization and has some potential upcoming trial milestones.
- An updated analysis around Vir Biotechnology follows in the paragraphs below.
Vir Biotechnology, Inc. ( VIR ) posted first quarter results after the bell on Thursday. The report contained some positive tidbits for its long-beleaguered shareholders, and it was more than enough for me to maintain my stake in this small-cap biotech firm, despite its numerous stumbles, via covered call holdings. The latest of these setbacks occurred last summer, when Vir's monoclonal antibody, which was targeted at the prevention of influenza A, did not meet its primary endpoint....
Read the full article on Seeking Alpha
For further details see:
Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders